Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,405 across all filing types
Latest filing 2026-04-27 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Saphnelo self-administration approved in the US
Regulatory Filings Classification · 85% confidence The document is an RNS press release by AstraZeneca PLC announcing FDA approval of a new self-administration autoinjector for their drug Saphnelo. It is not an earnings release, financial report, management discussion, or any corporate action like M&A, dividends, or share changes. It is a general regulatory/news announcement distributed via the Regulatory News Service (RNS), fitting the fallback category for miscellaneous regulatory filings.
2026-04-27 English
Group of companies' accounts made up to 2025-12-31
Regulatory Filings
2026-04-25 English
6-K - ASTRAZENECA PLC (0000901832) (Filer)
Regulatory Filings
2026-04-23 English
Directorate change
Board/Management Information Classification · 95% confidence The document is an RNS announcement titled “Change to AstraZeneca Board of Directors,” describing the departure of Rene Haas as a Non-Executive Director and his replacement context. It is clearly an announcement of a board change rather than a financial report or other filing. This matches the Board/Management Information category.
2026-04-23 English
6-K - ASTRAZENECA PLC (0000901832) (Filer)
Regulatory Filings
2026-04-21 English
I CAN PhIII interim analysis met primary endpoint
Regulatory Filings Classification · 95% confidence The document is an RNS announcement from AstraZeneca PLC reporting positive interim Phase III clinical trial results for Ultomiris. It is not an earnings report, financial supplement, or formal regulatory form (e.g., 10-K, IR, ER). It is a press release via the London Stock Exchange’s Regulatory News Service (RNS), which falls under the general regulatory announcements/fallback category.
2026-04-21 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.